MD

Business Context and Reporting Period

Pediatrix Medical Group, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2001. The Company is the nation's leading provider of physician services at hospital-based neonatal intensive care units (NICUs) and perinatal practices. As of year-end, Pediatrix operated in 27 states and Puerto Rico, employing or contracting with 588 practicing physicians. A significant corporate event during the period was the acquisition of Magella Healthcare Corporation on May 15, 2001, via a stock merger valued at approximately $173.6 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 45.9% to $354.6 million. Approximately $86.5 million of this increase was attributable to new units from acquisitions (primarily the Magella merger), while same-unit revenue grew 7.6% due to improved collections and volume.
• Profitability: Net income nearly tripled to $30.4 million. Operating income surged 135% to $58.4 million, driven by revenue growth and improved operating leverage.
• Liquidity: Cash and cash equivalents increased significantly from $3.1 million to $27.6 million. The Company paid down its entire $23.5 million balance on its line of credit during 2001 and refinanced the facility to $100 million.
• Expense Increases: Practice salaries and benefits rose 33.1% to $197.6 million, and General and Administrative expenses increased 40.0% to $62.8 million, largely due to the integration of Magella and expanded billing operations.

Guidance, Outlook, Risks, and Contingencies

Outlook and Strategy: Management intends to continue growth through acquisitions and same-unit expansion. The Company is developing regional networks to strengthen relationships with managed care payors. No specific numerical guidance for 2002 was provided in the text.

Legal and Regulatory Risks:

• Billing Investigations: Active and ongoing criminal, civil, and administrative investigations by Colorado Medicaid and Tricare regarding billing practices. Settlements were reached in Florida ($40,000) and Arizona ($220,000) in 2000, but inquiries in other states continue.
• Securities Litigation: The Company reached a definitive agreement to settle a securities class action lawsuit for $12.0 million. This amount is accrued as a liability but is expected to be fully covered by insurance.
• Accounting Changes: The Company adopted FAS 142 in 2002, which eliminates the amortization of goodwill. While this will reduce future expenses by approximately $20.3 million annually, it requires annual impairment testing which could result in significant write-downs if asset values decline.
• Insurance: Professional liability insurance premiums are expected to increase, and the Company is reviewing options for higher self-insured retentions.

Investor Verification Checklist

• Goodwill Impairment: Verify the results of the FAS 142 transitional impairment test for goodwill (approx. $497.7 million) expected in Q1 2002.
• Regulatory Outcomes: Monitor the status of the Colorado Medicaid and Tricare investigations for potential fines or retroactive revenue adjustments.
• Insurance Coverage: Confirm that the $12.0 million securities litigation settlement is fully indemnified by insurance carriers.
• Reimbursement Rates: Assess the impact of the shifting payor mix (23% government, 49% managed care) on future net revenue per patient.
• Integration Synergies: Evaluate whether the Magella acquisition has achieved projected cost savings and revenue synergies as same-unit growth stabilizes.